What is Standard BioTools Inc.'s market cap?

Standard BioTools Inc. (LAB) has a market capitalization of $244.7M and trades on NASDAQ.

Who are Standard BioTools Inc.'s competitors?

Standard BioTools Inc.'s key competitors include 10x Genomics, Bio-Rad Laboratories, Thermo Fisher Scientific, and others. These companies compete in similar markets and product categories.

Who does Standard BioTools Inc. partner with?

Standard BioTools Inc.'s notable partners include Illumina, California Institute of Technology, Harvard University, and others.

Where is Standard BioTools Inc. headquartered?

Standard BioTools Inc. is headquartered in United States of America and employs approximately 539 people. It has been publicly traded since 2011.

Standard BioTools Inc. (LAB) Stock Fundamentals & Financials

Standard BioTools is a life science tools company that provides essential, standardized solutions for biomedical research and drug development.

Market cap

$244.72M-44.2%

Earnings

Q2 2026 report

August 5, 2026

Revenue$20.1MMiss by $700.4K EPS-$0.07Miss by $0.06

Read the full report

Next report

Nov 3, 2026 (Tomorrow)

Revenue estimate$18.8M

EPS estimate-$0.02

Competitors

By market cap

Thermo Fisher Scientific$262.22B+24.8%

Agilent Technologies$51.1B+25.7%

Revvity$18.5B+75.1%

TEC

Bio-Techne Corp.$11.4B+20.3%

10x Genomics, Inc.$10.6B+586%

Bio-Rad Laboratories$10.3B+25.1%

Quantum-Si Incorporated$383.0M-11.9%

Standard BioTools Inc.$244.7M-44.3%

By revenue growth

Agilent Technologies+8.6%

Revvity+4.1%

Bio-Rad Laboratories+1.4%

TEC

Bio-Techne Corp.-0.4%

10x Genomics, Inc.-4.3%

By net margin

Agilent Technologies19.53%+1.6pp

Thermo Fisher Scientific15.19%—

TEC

Bio-Techne Corp.14.97%—

Bio-Rad Laboratories8.59%-3.9pp

Revvity8.16%-2.0pp

10x Genomics, Inc.-12.18%+0.9pp

Profile

Standard BioTools is a life science tools company that provides essential, standardized solutions for biomedical research and drug development. The company offers a diverse portfolio of instrumentation, consumables, and services focused on high-dimensional proteomics and genomics. Its core value proposition lies in enabling researchers to extract deep biological insights from complex samples through advanced mass cytometry and microfluidics technologies.

Competitive position

The company is a specialized provider of high-parameter protein analysis and microfluidic genomic tools, positioning itself as an alternative to traditional flow cytometry and bulk genomic methods.

GeographiesNorth America, Europe, Asia-Pacific, Latin America, Middle East

Customer segmentsAcademic institutions, Biopharmaceutical companies, Clinical laboratories

Business modelRazor-and-blade, Equipment manufacturing, Consumables and reagents, OEM licensing

SuppliersSole-source metal suppliers, Specialized microfluidic component manufacturers, Antibody and reagent chemical suppliers

CustomersPrincipal investigators, Laboratory directors, Drug discovery researchers, OEM partners

CountryUnited States of America

Listed2011

Employees539.0

CEOMichael Egholm

SectorHealthcare

IndustryMedical - Diagnostics & Research

Websitestandardbio.com

FilingsSEC EDGAR

FAQ

What is Standard BioTools Inc.'s market cap?: Standard BioTools Inc. (LAB) has a market capitalization of $244.7M and trades on NASDAQ.
Who are Standard BioTools Inc.'s competitors?: Standard BioTools Inc.'s key competitors include 10x Genomics, Bio-Rad Laboratories, Thermo Fisher Scientific, and others. These companies compete in similar markets and product categories.
Who does Standard BioTools Inc. partner with?: Standard BioTools Inc.'s notable partners include Illumina, California Institute of Technology, Harvard University, and others.
Where is Standard BioTools Inc. headquartered?: Standard BioTools Inc. is headquartered in United States of America and employs approximately 539 people. It has been publicly traded since 2011.